Victor Micati
Vorsitzender bei Oligomerix, Inc.
Profil
Victor P.
Micati is currently the Chairman at Oligomerix, Inc. since 2010, an Independent Director at Origin Life Sciences, Inc. since 2014, and the Director at Monterey Institute of International Studies.
Previously, he worked as a Director at Enzon Pharmaceuticals, Inc. from 2004 to 2010, a Director at ILEX Oncology, Inc., and served as the Executive Vice President-Pharmaceutical Group at Pfizer Inc. from 1965 to 1999.
Mr. Micati holds an MBA from The Trustees of Columbia University in The City of New York and an undergraduate degree from Middlebury College.
Aktive Positionen von Victor Micati
| Unternehmen | Position | Beginn |
|---|---|---|
| Monterey Institute of International Studies | Direktor/Vorstandsmitglied | - |
Oligomerix, Inc.
 Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Vorsitzender | 01.07.2010 |
Origin Life Sciences, Inc.
 Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | Direktor/Vorstandsmitglied | 01.09.2014 |
Ehemalige bekannte Positionen von Victor Micati
| Unternehmen | Position | Ende |
|---|---|---|
| ENZON PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | - |
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Direktor/Vorstandsmitglied | 28.03.2006 |
| PFIZER, INC. | Corporate Officer/Principal | 01.01.1999 |
Ausbildung von Victor Micati
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Middlebury College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ENZON PHARMACEUTICALS, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
ILEX Oncology, Inc.
ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Retail Trade |
Origin Life Sciences, Inc.
Origin Life Sciences, Inc. BiotechnologyHealth Technology Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ. | Health Technology |
